Cutia Therapeutics (HK:2487) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cutia Therapeutics’ CEO and Executive Director, Ms. Zhang Lele, demonstrated her confidence in the company by purchasing 8,000 additional shares with her personal funds, signaling potential growth and stability to shareholders and investors. The company has assured that it maintains the required public float in compliance with Hong Kong’s listing rules, post-purchase. Shareholders are cautioned to exercise prudence when dealing in company shares.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.